Precigen, Inc.
IN VIVO CONTROLLED COMBINATION THERAPY FOR TREATMENT OF CANCER

Last updated:

Abstract:

Disclosed herein are improved methods for treatment of brain cancer (such as glioma/glioblastoma) via ligand-inducible gene-switch controlled in vivo expression of an immunomodulator (i.e., IL-12) in combination with one or more other immunomodulators (i.e., an immune cell check point inhibitor; e.g., such as a PD-1 inhibitor or a PD-1 binder.

Status:
Application
Type:

Utility

Filling date:

27 Jun 2019

Issue date:

23 Dec 2021